发明名称 NOVEL USE OF ANTI IL-1BETA ANTIBODIES
摘要 This disclosure relates to a novel use of IL-1²-ligand/IL-1 receptor disrupting compounds (herein referred to as "IL-1 beta Compounds"); such as small molecular compounds disrupting IL-1² ligand -IL-1 receptor interaction, IL-1² antibodies or IL-1 receptor antibodies, e.g. IL-1² binding molecules described herein, e.g. anti- bodies disclosed herein, e.g. IL-1² binding compounds or IL-1 receptor binding compounds, and/or RNA com- pounds decreasing either IL-1² ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid ar thritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.
申请公布号 EP1940465(B1) 申请公布日期 2012.08.01
申请号 EP20060826560 申请日期 2006.10.24
申请人 NOVARTIS AG;NOVARTIS PHARMA GMBH 发明人 LOWE, PHIL;GRAM, HERMANN;JUNG, THOMAS;WRIGHT, TIMOTHY;MUNDEL, TREVOR
分类号 A61K39/395;A61P19/02;A61P37/00;C07K16/24 主分类号 A61K39/395
代理机构 代理人
主权项
地址